-
James Van Der Beek, Jenna Fischer and the rise of young people getting cancer
Dr. John Marshall cautions both patients and medical professionals to not brush away concerning symptoms just because someone is young in this USA Today article
Category: News
-
Zolbetuximab/Chemo Displays PFS, OS Benefits in Gastric Cancer Trials
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
Category: News
-
Treatment Personalization Is Poised to Define New Era of mCRC Therapy
“When you have a patient with a RAS mutation, don’t just close it up and say, ‘I have [a patient with] a RAS mutation.’ You must know which RAS mutation it is and note that because you now have access to KRAS G12C inhibitors in this population,” John Marshall, MD, added.
Category: News
-
Zolbetuximab Has Benefit in Targeting CLDN18.2 in Gastrointestinal Cancers
Dr. Marshall discusses the incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Category: News
-
Young Adults With Colon Cancer May Be Hit by More Aggressive Disease
Their cancer also tends to be diagnosed later, researchers say. But there are steps they can take to reduce their risk.
Category: News
-
Increased ctDNA and MMR Testing May Alter Adjuvant and Neoadjuvant CRC Management
Benjamin Adam Weinberg, MD, discusses the prognostic value of adjuvant ctDNA testing in CRC and the role of immune checkpoint inhibition in dMMR CRC.
Category: News
-
Colorectal cancer survivor diagnosed at 40 showed almost no symptoms – except this one
“We evolved over time to include bacteria in our mouths and our GI tracts. Think of it as your own personal soil,” Dr. John L. Marshall said. “So, our leading theory is: Just like we’re changing our air and we’re changing our water with the world around us, we are probably also changing the world inside of us, our own microbiome.”
Category: News
-
FDA Approves First Blood Test Screening for CRC
“This is a new way to test for if you have an early cancer or an early polyp in the colon that doesn’t involve your poop, that doesn’t involve a bowel prep,” John Marshall, MD said. “So for a lot of people, this means you’ve got no more excuse not to get screening for colon cancer.”
Category: News
-
ctDNA Testing Could Lead to New Ways of Staging Cancer Patients
ctDNA, or circulating tumor DNA, is now used as a biomarker in new testing to detect cancer—or its absence —in a patient’s blood. Dr. Weinberg discusses his research.
Category: News
-
Overview of Molecular Testing and Barriers in mCRC
Evolving Treatments of Metastatic CRC: Insights from ASCO 2024. Dr. Marshall gives an overview of mMolecular testing and barriers in mCRC
Category: News